Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Shiseido Arbitration

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Aug 15, 2022 10:28am

118 Views

Post# 34896385

RE:RE:RE:RE:Shiseido Arbitration

This from Twitter Oct. 17th 2020:

" RepliCel Life Sciences Inc.

@RepliCel

Oct 17, 2020

 			Aside from all the ways we know this is the same product , we own the patents on autologous dermal sheath cup cells for the treatment of hair loss due to androgenic alopecia."
 			
 			Regardless on how this arbitration is judged, with these RCH-01 patents being held by Replicel Shiseido has breached this patent by continuing to use RCH-01 in their current trial. This Trial was started in October 2020 and I am sure after 2 years it has been completed. I sense that Shiseido is sitting on the results.
 			
 			There is a good chance if the results of the trial were encouraging and Shiseido would like to take the procedure to market they have no choice but to make a deal with Replicel. The question is what kind of deal. 